Depletes Folic Acid. This medication is commonly used for Stomach Acid
Research suggests that long-term use of H2 blockers and antacids might raise the risk of folic acid deficiency. These medications work by reducing stomach acid, which can also play a role in folic acid absorption. Folic acid is crucial for healthy cell growth and development, and a deficiency can lead to various health problems, especially during pregnancy. Some studies show a potential link between H2 blocker/antacid use and lower folic acid levels. Individuals who take H2 blockers or antacids for extended periods should consider supplementation with folic acid to protect against a deficiency.
Russell RM, Golner BB, Krasinski SD, Sadowski JA, Suter PM, Braun CL. Effect of antacid and H2 receptor antagonists on the intestinal absorption of folic acid. J Lab Clin Med. 1988 Oct;112(4):458-63. Prescott JD, Drake VJ, Stevens JF. Medications and Micronutrients: Identifying Clinically Relevant Interactions and Addressing Nutritional Needs. J Pharm Technol. 2018 Oct;34(5):216-230.
Folate ( .2mg as L-5-Methylfolate) — 0.34 mg DFE
Low folate status contributes to elevated homocysteine, a metabolite that has been associated with endothelial dysfunction, arterial stiffness, and a higher risk of stroke and coronary heart disease. Large observational studies consistently show that individuals with higher homocysteine levels have greater rates of cardiovascular events, and folate intake is one of the key nutritional determinants of homocysteine. Clinically, folic acid supplementation (often combined with vitamins B6 and B12) can lower homocysteine and appears to modestly reduce stroke risk in some populations, making the identification and correction of folate deficiency an important part of broader cardiovascular risk reduction.
Folate deficiency in the periconceptional period significantly increases the risk of neural tube defects (NTDs) such as spina bifida and anencephaly, because adequate folate is required for proper closure of the embryonic neural tube in the first month of pregnancy. Large observational datasets and randomized trials have shown that appropriate folic acid supplementation before conception and in early pregnancy can reduce NTD risk by roughly 50–70% in the general population, with even greater risk reduction in women with a prior NTD‑affected pregnancy. The practical implication is that all women of childbearing potential, not just those actively planning pregnancy, are typically advised to maintain adequate daily folic acid intake so that red‑cell folate stores are sufficient well before conception occurs.